Cargando…

Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells

Metronomic oral vinorelbine (VRL; Navelbine) was shown in clinical trials to yield sustainable antitumor activity possibly through antiangiogenic mechanisms. We investigated the effects of protracted low-dose VRL on human umbilical vein endothelial cells, compared with a conventional chemotherapy mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biziota, Eirini, Briasoulis, Evangelos, Mavroeidis, Leonidas, Marselos, Marios, Harris, Adrian L., Pappas, Periklis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Preclinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733659/ https://www.ncbi.nlm.nih.gov/pubmed/26629767 http://dx.doi.org/10.1097/CAD.0000000000000319

Ejemplares similares

Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition
por: MAVROEIDIS, L., et al.
Publicado: (2015)

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
por: Briasoulis, Evangelos, et al.
Publicado: (2013)

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
por: Qin, Rong-Sheng, et al.
Publicado: (2018)

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study
por: Liu, Chien-Ting, et al.
Publicado: (2021)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
por: Krajnak, Slavomir, et al.
Publicado: (2023)

Expression Profile of Genes Related to Drug Metabolism in Human Brain Tumors
por: Stavrinou, Pantelis, et al.
Publicado: (2015)

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer
por: Pujol, Jean-Louis, et al.
Publicado: (2019)

Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience
por: Rossi, David
Publicado: (2020)

Abstract 27 Secretome of Umbilical Cord Mesenchymal Stem Cells: Potential Effects on Melanoma
por: Fernandes, Pablo, et al.
Publicado: (2023)

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial
por: Guetz, Sylvia, et al.
Publicado: (2017)

Abstract 29 Umbilical Cord-derived Mesenchymal Stromal Cells Suppress Microglia Activation Induced by Demyelination
por: Xu, Li, et al.
Publicado: (2023)

Abstract 4 Umbilical Cord-Derived Mesenchymal Stromal Cells Suppress Neuroinflammation and Promote Remyelination in the Spinal Cord
por: Min, Hyunjung, et al.
Publicado: (2022)

Abstract 32 Expanded Umbilical Cord Blood CD34+ Cells Are Immunomodulatory in a Rat Model of Neonatal Brain Injury
por: Penny, Tayla, et al.
Publicado: (2023)

Abstract 31 Chagas Disease Screening in Pregnancy: Lessons from Screening Maternal Donors from Publicly Banked Umbilical Cord Blood
por: Rosen, Melissa, et al.
Publicado: (2023)

Abstract 5 Human Umbilical Cord Blood-Derived Cell Therapy Product, DUOC-01, Promotes Remyelination by Driving the Differentiation of Oligodendrocyte Progenitor Cells
por: Xu, Li, et al.
Publicado: (2022)

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020)

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
por: Chi, Yajing, et al.
Publicado: (2022)

Pleiotropic, Cellular Effects of Rivaroxaban on Autophagy Explain Atheroprotective Effects
por: Posma, Jens J.N., et al.
Publicado: (2021)

Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer
por: D'Ascanio, Michela, et al.
Publicado: (2018)

Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine
por: Bijnsdorp, Irene V., et al.
Publicado: (2009)

Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype
por: Vanags, Laura Z., et al.
Publicado: (2018)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018)

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
por: Barlesi, Fabrice, et al.
Publicado: (2017)

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab
por: Villard, Elise F., et al.
Publicado: (2016)

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
por: Chemello, Kévin, et al.
Publicado: (2020)

MODL-05 Metronomic Intrathecal Delivery of CDK4/6 Inhibitors in Preclinical Models of Pediatric Brain Tumors
por: Guadix, Sergio, et al.
Publicado: (2022)

The cellular effects of novel triazine nitrogen mustards in glioblastoma LBC3, LN-18 and LN-229 cell lines
por: Krętowski, Rafał, et al.
Publicado: (2019)

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
por: Kusaczuk, Magdalena, et al.
Publicado: (2016)

Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines
por: Wróbel, Agnieszka, et al.
Publicado: (2019)

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
por: Cazzaniga, M. E., et al.
Publicado: (2014)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
por: Camerini, Andrea, et al.
Publicado: (2015)

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
por: Vicier, C., et al.
Publicado: (2022)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

Comment on: “Disulfiram-induced De novo Convulsions Without Alcohol Challenge: Case Series and Review of Literature” (Kulkarni and Bairy, Indian J Psychol Med, Jul-Sep; 37(3): 345-8, 2015)
por: Karamanakos, Petros N., et al.
Publicado: (2016)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
por: Froudarakis, Marios E, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_gh7qu6jl3ca6nju0gopv95ao66